HDAC INHIBITOR AND BTK INHIBITOR COMBINATIONS
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
N/A
app pub date -
Jun 4, 2015
filing date -
Jun 4, 2014
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
Disclosed herein are methods and compounds for treating an individual diagnosed with chronic lymphocytic leukemia (CLL) or acute myeloid leukemia (AML) by administering to the individual a combination comprising ibrutinib and Abexinostat. Also provided are methods for treating an ibrutinib-resistant CLL or an ibrutinib-resistant AML by administering to the individual a combination comprising ibrutinib and Abexinostat. Further provided are methods of reducing the development of ibrutinib resistance in an individual having either CLL or AML or preventing the development of ibrutinib resistance in an individual having CLL or AML by administering to the individual a combination comprising ibrutinib and Abexinostat.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully